| 1 |
35020157 | Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. | 2022 Mar |
1 |
| 2 |
33597189 | Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. | 2021 May |
1 |
| 3 |
32414131 | CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. | 2020 May 13 |
1 |
| 4 |
33189062 | Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS). | 2020 Nov 5 |
1 |
| 5 |
30644981 | Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. | 2019 Jan 15 |
1 |
| 6 |
29497558 | Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. | 2018 Jan-Mar |
1 |
| 7 |
29521113 | Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. | 2018 May |
1 |
| 8 |
29974307 | Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity. | 2018 Oct |
1 |
| 9 |
27857690 | Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. | 2016 |
1 |
| 10 |
25546031 | Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. | 2015 Mar |
1 |
| 11 |
25876471 | Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. | 2014 May |
1 |
| 12 |
25876473 | Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). | 2014 May |
2 |
| 13 |
23738997 | Fingolimod for the treatment of relapsing multiple sclerosis. | 2013 Jun |
1 |
| 14 |
24139422 | Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. | 2013 Oct |
1 |
| 15 |
22494956 | Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. | 2012 May |
1 |
| 16 |
21751747 | Fingolimod. | 2011 Jul-Aug |
1 |